|Articles|December 15, 2003
Injection application accepted by FDA
The FDA is weighing the application by Amphastar Pharmaceuticals Inc. for a hyaluronidase injection 150 units/ml, 1ml.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA extends Aldeyra's reproxalap PDUFA after requesting additional clinical study report
2
Aviceda Therapeutics reports positive phase 2b SIGLEC results for AVD-104 in geographic atrophy
3
Argenx discontinues phase 3 UplighTED trials of efgartigimod SC in thyroid eye disease
4
Managing challenging pterygium removal: Amniotic membrane grafting strategies
5








































.png)


